Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

J Transl Med. 2024 Jul 26;22(1):680. doi: 10.1186/s12967-024-05362-w.

Authors

Yu Wang¹, Yu-Juan Xue¹, Ying-Xi Zuo¹, Yue-Ping Jia¹, Ai-Dong Lu¹, Hui-Min Zeng², Le-Ping Zhang¹

Affiliations

¹ Department of Pediatrics, Peking University People's Hospital, Peking University, No.11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
² Department of Pediatrics, Peking University People's Hospital, Peking University, No.11, Xizhimen South Street, Xicheng District, Beijing, 100044, China. [email protected].

No abstract available

Publication types

Letter

MeSH terms

Adult
Antigens, CD19* / immunology
Female
Humans
Immunotherapy, Adoptive* / methods
Male
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Receptors, Chimeric Antigen
Recurrence
Treatment Outcome

Substances

Antigens, CD19
Receptors, Chimeric Antigen

Grants and funding